Our Research Strategy
Because research will beat blood cancer.
Research is at the heart of what we do. Over the last 60 years, we have invested over £500 million in research and this has led to key discoveries that have changed lives. We believe it’s now possible to beat blood cancer in a generation.
- Gemma Peters, CEO of Blood Cancer UK
Our research strategy in summary
As Blood Cancer UK, we bring together patients and people affected by blood cancer, with a vibrant, world-class community of blood cancer researchers. Our future research investment will be driven by a focus on both impact and patient priorities.
We will fund across a diverse portfolio, allowing us to take risks, respond to emergent opportunities and partner with others on common goals. This portfolio will include competitive project grant funding against a set of defined priorities. We will also introduce a cross cutting scheme, that will allow us to support initiatives and research programmes across blood cancers.
Investing in partnership with other funders will allow Blood Cancer UK to bring new investment into blood cancer research and we will identify specific opportunities for co-funding.
Blood Cancer UK has had a strong track record in funding for early career researchers, and we will introduce a new fellowship scheme to support career development and the next generation of blood cancer researchers.
Our vision & mission
We're here to beat blood cancer, and research will get us there.
Over the last 60 years we have proved that blood cancer research saves lives, but now we need to finish the job. We need to discover more about how blood cancers evolve, develop, and are best treated. We need treatments with fewer side effects and better outcomes for people affected by blood cancer. We want a world where we can predict how a disease will progress, so that we can stop blood cancer in its tracks. Because the more we understand it, the more lives we can save.
If cancer research were a comet, blood cancer research would be the brightest part at the leading edge. Many of the paradigm shifts in cancer research have come from research into blood cancer: chemotherapy, targeted therapies, CAR-T, etc.
- Chris Bunce, Professor of Translational Cancer Biology, University of Birmingham
Blood Cancer UK is the largest sole blood cancer research funder in the UK. Funding research which has an impact across all blood cancers is particularly important. Blood cancers are interconnected, as is the experience of people affected by blood cancer and the clinicians who treat them. For example, chronic lymphocytic leukaemia (CLL) can transform to non-Hodgkin lymphoma and myelodysplastic syndromes (MDS) to acute myeloid leukaemia (AML).
We know from previous discoveries that new treatments in one blood cancer go on to work in others, for example CAR-T. It is also true that developments in blood cancer have benefited other cancers and biomedical science. In blood cancer, we’ve identified the “cancer stem cell” responsible for generating a stream of cancer cells and causing drug resistance. Many cancer researchers across the globe are now trying to find treatments that target these cells.
As Blood Cancer UK, we are in a prime position to act on these opportunities. We bring together people affected by blood cancer, researchers and health care professionals to ensure we are focused on what matters most as well as funding the best quality science that will lead to the advances in treatment and outcomes. Because we’re stronger together.
Nothing about us without us, to quote the well-known phrase. Being involved in this process has helped me understand just how important the patient voice is to Blood Cancer UK. We have been listened to at every step.
- Ally Boyle, diagnosed with myelodysplastic syndrome (MDS) in 2008
Our core strategic principles
Across our portfolio, Blood Cancer UK is committed to funding excellent quality scientific research that will improve our understanding of blood cancers, lead to the development of new treatments with fewer side effects and will ensure that more people survive. As a result of the research strategy development process, Blood Cancer UK will focus on doing five things:
- Working in partnership – We will actively seek to work with other charities, industry and partners who share common goals, in the UK and internationally.
- Driving innovation – our researcher and patient community will continue to shape our priorities. Our funding approach will be agile to enable us to respond to emerging opportunities.
- Facilitating collaboration/ multi-disciplinary research - there are many complex challenges in blood cancer research that will require ideas and expertise from multiple disciplines. We know a collaborative approach will be important in making a step change for people affected by blood cancer.
- Putting people affected by blood cancer at the heart of research – people affected by blood cancer have guided the development of this research strategy and we will continue to ensure their voice is central to our research.
- Working collaboratively with researchers – we will continue to work with researchers to make sure our priorities are in line with new discoveries and will have the biggest impact on people affected by blood cancer. It is critical the very best people work on blood cancer research and so we will invest in careers.
No one can predict the course of research, and as a result researchers need an avenue for funding that allows them to present innovative ideas, which might in turn uncover something ground-breaking.
- Tim Somervaille, Professor of Haematological Oncology, Cancer Research UK Manchester Institute
Overview of our research portfolio
- Competitive Grant Funding Scheme
Description: Applications will be considered by our funding committee and approved for funding where they demonstrate alignment with our priorities (page 9) and are of high scientific quality.
Rationale: Enables us to continue to fund high quality projects, whilst allowing for scientific innovation, but prioritising identified areas.
- Early Careers
Description: Joint funding scheme with partner funder to support early career researchers.
Rationale: Supports the future of blood cancer researchers, such as emerging group leaders.
- Strategic Investment
Description: Investment in specific and strategic research opportunities that have the potential to transform the lives of people with blood cancer
Rationale: Blood Cancer UK is strategically positioned to connect donors and researchers.
- Multidisciplinary Scheme
Description: One funding call per year for multi-collaborative applications.
Rationale: Encourages research across multiple blood cancers and supports collaboration and the formation of broader blood cancer research teams.
- Funding Partnerships
Description: Blood Cancer UK will join with other funders to strategically combine funding in areas of specific need. Most recently, we have done this to support vaccine effectiveness research.
Rationale: Enables a specific scheme for partnership with other charities and funders, to encourage less duplication and target areas of need.
Working in partnerships is so important to make the most of the funding available and achieve more for patients.
- Irene Roberts, Professor of Paediatric Haematology, Oxford University
Our priorities for this year (FY 2021/22)
This year, we will prioritise three areas of research investment, within our competitive grant funding scheme.
- Improving understanding of fundamental disease processes - including underlying areas such as disease origin, transformation, and relapse, so that we can better predict, and in the future prevent, blood cancer.
- Improving treatment options for the individual - including personalised approaches and immunotherapies, resulting in improved survival with fewer side effects (due to less toxic treatments).
- Developing novel approaches to the use of data - advancing our understanding through analysing large and rich data sets to facilitate benefits across blood cancers.
As someone living with and being treated for CLL, there will always be a constant worry in my mind about my blood cancer transforming into Richter’s syndrome, a much more aggressive form of blood cancer, with few treatment options.
- Kieron Mayes, diagnosed with chronic lymphocytic leukaemia (CLL) in 2009